ENDONOVO THERAPEUTICS, INC. (OTCMKTS:ENDV) Files An 8-K Entry into a Material Definitive AgreementItem 1.01
As previously reported in a Current Report on Form 8-K filed December 26, 2017, certain assets of the Company, primarily intellectual property (the “Assets”), were held subject to a $1,500,000 secured promissory note (the “Note”) due November 30, 2018 and payable to Steven Gluckstern. On November 29, Eagle Equities, LLC (“Eagle”) purchased the Note from Gluckstern for its face value. to an Exchange Agreement, dated as of November 30, 2018 but executed December 7, 2018 (“the Exchange Agreement”), the Company issued a replacement secured note called the 10% Senior Secured Convertible Redeemable Note Due November 30, 2019 (the “Replacement Note”) to Eagle in the principal amount of $1,500,000. The Replacement Note continues Eagle’s a first priority lien on the Assets, bears interest at 10% per annum, is due November 30, 2019, is convertible into the Company’s common stock at prices determined with reference to the market prices of the Company’s Common Stock and is redeemable by the Company at a premium.
The foregoing is only a summary of the Exchange Agreement and the New Note which are filed as exhibits hereto. The reader is directed to such exhibits for a full description of the Exchange Agreement and the New Note.
|Item 9.01||Financial Statements and Exhibits.|
|(a)||Financial Statements -None|
ENDONOVO THERAPEUTICS, INC. ExhibitEX-10.1 2 ex10-1.htm EXCHANGE AGREEMENT THIS EXCHANGE AGREEMENT (the “Agreement”) is as of November 30,…To view the full exhibit click
About ENDONOVO THERAPEUTICS, INC. (OTCMKTS:ENDV)
Endonovo Therapeutics, Inc., formerly Hanover Portfolio Acquisitions, Inc., is a biotechnology company developing a bioelectronic approach to regenerative medicine. The Company operates through two segments: intellectual property licensing and commercialization, and biomedical research and development, which includes development of its square wave form device. Its Immunotronics platform is a non-invasive, non-implantable bioelectronic device for treating/preventing vital organ failure through the reduction of inflammation and cell death. Its Cytotronics platform is being developed to create biologically potent cell therapies. It is using this technology to create a therapy for the treatment of Graft-Versus-Host Disease (GvHD), a rare complication following allogeneic tissue transplants. Its Cytotronics platform provides for a method of expanding and manipulating cells using simulated microgravity and Time-Varying Electromagnetic Fields for tissue engineering and cell therapies.